News
ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East
ArisGlobal, the leading provider of life sciences software that automates core drug development functions with its end-to-end technology platform LifeSphere®, announces significant growth in the global footprint of its LifeSphere Clinical software, following the customer wins of two prominent...
News
CPHI North America opens as 65% of US companies forecast growth in excess of 20% in 2022
Kicking off the season for pharmaceutical professionals to come together digitally (09-27 May, 2022) as well as in-person (17-19 May, 2022). CPHI North America will be held as a SMART event, with three weeks of dedicated pharma learning and partnering.
The benefit for...
News
Sepha’s new EZ Blister+ enables 21 CFR Part 11 compliant micro-batches
Sepha, the Northern Ireland-based manufacturer of pharmaceutical packaging and equipment, has developed a new compact small-batch blister packaging machine with full traceability and electronic data storage capabilities. The EZ Blister+ meets increased demand for 21 CFR Part 11 compliant...
News
Moderna Jab For Kids Upto 6 Years 44% Apt Against Omicron
According to the data presented by Moderna, the two-dose COVID vaccination was around 44% effective in preventing omicron infection in children aged 6 months to under 2 years, and about 38 percent effective in children aged 2 to 5.
As...
News
COVID-19 Vaccine On Its Way To Becoming An Yearly Affair
Public health experts aren't sure what the future has in store for COVID-19 immunizations, but some think it's becoming increasingly likely that these doses will be required on an annual basis, similar to the way flu shots are advised each...
News
Abzena Secures $65 Million in Additional Funding to Accelerate Growth and Expand Capacity
Abzena, a leading global contract development and manufacturing organization (CDMO) providing integrated discovery, development, and manufacturing of biologics and antibody drug conjugates (ADCs), announced a new round of investment. Funding sources for the additional $65 million include majority-owner Welsh,...
News
Rokote Laboratories selects Exothera for GMP manufacturing of its second-generation coronavirus vaccine FINCoVac 2.0.
Rokote Laboratories Finland Ltd., a vaccine development company focusing on a second-generation COVID-19 vaccine, and Exothera S.A. will collaborate to bring the intranasal coronavirus vaccine FINCoVac 2.0 to clinical Phase I/II trials. Exothera will finetune the industrialization of the...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.















